What does Pharma4Future do?

Pharma4Future is registered with the CBE as active in: Activiteiten van holdings. Private Limited, started on 22 October 2021, 1 establishment.

What is the address of Pharma4Future?

The registered office of Pharma4Future is located at Heiveld 29 box 101, 1745 Opwijk.

Is Pharma4Future still active?

Yes. According to the CBE (29 October 2026) Pharma4Future is active, legal situation “Normale toestand”, started on 22 October 2021.

Is Pharma4Future registered on Peppol?

Yes, Pharma4Future is registered on the Peppol network with ID 0208:0776403737.

What is the enterprise number of Pharma4Future?

The enterprise number of Pharma4Future is BE0776403737.

When was Pharma4Future founded?

Pharma4Future was founded on 22 October 2021.

Who are the directors of Pharma4Future?

According to the 2025 annual accounts, the directors of Pharma4Future are: THE WALL COMPANY, Pharma Officinalis, TOURNOV.

Is Pharma4Future a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 22 October 2021; 4 annual accounts filed, latest fiscal year 2025; 3 directors known from the annual account.

How much profit did Pharma4Future make in 2025?

Pharma4Future posted a profit after taxes of € 246,977 in financial year 2025.

What is the revenue of Pharma4Future?

As a small company, Pharma4Future is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 447,474.

Pharma4Future (Private Limited) - Opwijk - BE0776403737

Dossier Pharma4Future, printed on 29 October 2026 from databakkes.be/en/0776403737/pharma4future. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 4 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

Pharma4Future from Opwijk, company number BE0776403737, closed financial year 2025 with a result of € 246,977 after tax. For that financial year Pharma4Future recorded a gross margin of € 447,474 and equity of € 563,772. Compared with financial year 2024, the result moved from € 129,711 to € 246,977. Profitable, and profit is growing. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 2, 2026.

What it is worth Growing

€ 563,772

▲ 78% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 246,977

▲ 90% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 32,478

▲ 29% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 553,772.

Debts at end 2025

Bank debt ≈ 10 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 3.7 million

▼ 8% vs 2024

€ 353,110 is repaid this year. At this pace the long-term loan is gone in ≈ 10 years.

Owed to suppliers

€ 4,490

▲ 75% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 21,866

▲ 4% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 206,009 Gross margin 2022: € 206,009 First fiscal year in the series	€ 228,086 Gross margin 2023: € 228,086 ▲ 11% vs 2022 (€ 206,009) Favourable step	€ 260,352 Gross margin 2024: € 260,352 ▲ 14% vs 2023 (€ 228,086) Favourable step	€ 447,474 Gross margin 2025: € 447,474 ▲ 72% vs 2024 (€ 260,352) Favourable step	▲ 72%
Profit after taxes	€ 70,184 Profit after taxes 2022: € 70,184 First fiscal year in the series	€ 106,899 Profit after taxes 2023: € 106,899 ▲ 52% vs 2022 (€ 70,184) Favourable step	€ 129,711 Profit after taxes 2024: € 129,711 ▲ 21% vs 2023 (€ 106,899) Favourable step	€ 246,977 Profit after taxes 2025: € 246,977 ▲ 90% vs 2024 (€ 129,711) Favourable step	▲ 90%
Equity	€ 80,184 Equity 2022: € 80,184 First fiscal year in the series	€ 187,083 Equity 2023: € 187,083 ▲ 133% vs 2022 (€ 80,184) Favourable step	€ 316,795 Equity 2024: € 316,795 ▲ 69% vs 2023 (€ 187,083) Favourable step	€ 563,772 Equity 2025: € 563,772 ▲ 78% vs 2024 (€ 316,795) Favourable step	▲ 78%
Total debts	€ 3,713,450 Total debts 2022: € 3,713,450 First fiscal year in the series	€ 3,652,000 Total debts 2023: € 3,652,000 ▼ 2% vs 2022 (€ 3,713,450) Favourable step	€ 4,701,954 Total debts 2024: € 4,701,954 ▲ 29% vs 2023 (€ 3,652,000) Unfavourable step	€ 4,468,619 Total debts 2025: € 4,468,619 ▼ 5% vs 2024 (€ 4,701,954) Favourable step	▼ 5%
Cash	€ 64,102 Cash 2022: € 64,102 First fiscal year in the series	€ 28,046 Cash 2023: € 28,046 ▼ 56% vs 2022 (€ 64,102) Unfavourable step	€ 25,154 Cash 2024: € 25,154 ▼ 10% vs 2023 (€ 28,046) Unfavourable step	€ 32,478 Cash 2025: € 32,478 ▲ 29% vs 2024 (€ 25,154) Favourable step	▲ 29%
Land & buildings	€ 665,713 Land & buildings 2022: € 665,713 First fiscal year in the series	€ 640,974 Land & buildings 2023: € 640,974 ▼ 4% vs 2022 (€ 665,713) Unchanged	€ 616,234 Land & buildings 2024: € 616,234 ▼ 4% vs 2023 (€ 640,974) Unchanged	€ 591,495 Land & buildings 2025: € 591,495 ▼ 4% vs 2024 (€ 616,234) Unchanged	▼ 4%
Retained profit	€ 70,184 Retained profit 2022: € 70,184 First fiscal year in the series	€ 177,083 Retained profit 2023: € 177,083 ▲ 152% vs 2022 (€ 70,184) Favourable step	€ 306,795 Retained profit 2024: € 306,795 ▲ 73% vs 2023 (€ 177,083) Favourable step	€ 553,772 Retained profit 2025: € 553,772 ▲ 81% vs 2024 (€ 306,795) Favourable step	▲ 81%
Bank debt	€ 3,339,148 Bank debt 2022: € 3,339,148 First fiscal year in the series	€ 3,114,960 Bank debt 2023: € 3,114,960 ▼ 7% vs 2022 (€ 3,339,148) Favourable step	€ 3,987,567 Bank debt 2024: € 3,987,567 ▲ 28% vs 2023 (€ 3,114,960) Unfavourable step	€ 3,660,137 Bank debt 2025: € 3,660,137 ▼ 8% vs 2024 (€ 3,987,567) Favourable step	▼ 8%
Balance sheet total	€ 3,793,634 Balance sheet total 2022: € 3,793,634 First fiscal year in the series	€ 3,839,083 Balance sheet total 2023: € 3,839,083 ▲ 1% vs 2022 (€ 3,793,634) Unchanged	€ 5,018,749 Balance sheet total 2024: € 5,018,749 ▲ 31% vs 2023 (€ 3,839,083) Unchanged	€ 5,032,391 Balance sheet total 2025: € 5,032,391 Unchanged (€ 5,018,749) Unchanged

Key figures of Pharma4Future, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Pharma4Future?

What happened at Pharma4Future in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 2, 2026 New annual accounts for financial year 2025: profit of € 246,977 (▲ 90% vs 2024). Source: NBB ↗
Oct 22, 2021 New establishment in Opwijk. KBO
Oct 22, 2021 Start of the company according to the CBE. KBO
2021 THE WALL COMPANY became a director. NBB
2021 Pharma Officinalis became a director. NBB
2021 TOURNOV became a director. NBB

In short

From € 70,184 profit in 2022 to € 246,977 profit in 2025.

Paid € 184,758 in corporate taxes since 2022.

Best year ever: 2025, with € 246,977 profit.

Original PDFs at the National Bank ↗

Management

Elpers Farma 25%

THE WALL COMPANY 25%

Pharma Officinalis 25%

TOURNOV 25%

The stake of Elpers Farma, THE WALL COMPANY, Pharma Officinalis, TOURNOV comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

Pharma4Future

Apotheek Londerzeel 100%

Apotheek Breendonkfarma 100%

Behind Pharma4Future are THE WALL COMPANY, Pharma Officinalis and TOURNOV. The shares are held by Elpers Farma (25%), THE WALL COMPANY (25%), Pharma Officinalis (25%) and TOURNOV (25%). It owns 100% of Apotheek Londerzeel and 100% of Apotheek Breendonkfarma itself.